Intralipid/Heparin

PreclinicalSmall molecule

OOregon Health and Science University

Intralipid/Heparin is one of 7 small molecule programs targeting Insulin Sensitivity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin SensitivityCompleted

Insulin SensitivityPreclinical

Completed

Competition

Competitive Landscape

7 competitors in Insulin Sensitivity

#DrugCompanyPhaseTrials

Prolia

OOrganon and Co

Approved

1 2

Glucophage

EMD Serono

Phase 3

5 3

Livalo

MMedicure

Preclinical

1 4

Gnrh Ant

Merck & Co.

Preclinical

1 5

Growth Hormone

Pfizer

Preclinical

1 6

Somavert

PPharmacia and Upjohn

Preclinical

1 7

Intralipid/Heparin

OOregon Health and Science University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Insulin Sensitivity1 trial

Fatty Acid Oxidation Defects and Insulin Sensitivity

Completed·OOregon Health and Science University·N/A·NCT02517307·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intralipid/Heparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intralipid/Heparin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intralipid/Heparin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oregon Health and Science University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOregon Health and Science University

Intralipid/Heparin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Insulin Sensitivity1 trial

References

Drug Info

Quick Facts

Related News